Literature DB >> 24201214

CAR T cells for acute myeloid leukemia: the LeY of the land.

Malcolm K Brenner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24201214      PMCID： PMC3831052          DOI： 10.1038/mt.2013.234

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  12 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

Review 2.  Genetic modification of T cells.

Authors:  Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

3.  Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Authors:  Ekaterina Doubrovina; Taissia Carpenter; Dmitry Pankov; Annamalai Selvakumar; Aisha Hasan; Richard J O'Reilly
Journal:  Blood       Date:  2012-05-23       Impact factor: 22.113

4.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Authors:  David S Ritchie; Paul J Neeson; Amit Khot; Stefan Peinert; Tsin Tai; Kellie Tainton; Karen Chen; Mandy Shin; Dominic M Wall; Dirk Hönemann; Peter Gambell; David A Westerman; Javier Haurat; Jennifer A Westwood; Andrew M Scott; Lucy Kravets; Michael Dickinson; Joseph A Trapani; Mark J Smyth; Phillip K Darcy; Michael H Kershaw; H Miles Prince
Journal:  Mol Ther       Date:  2013-07-08       Impact factor: 11.454

5.  An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

Authors:  Anna Sergeeva; Gheath Alatrash; Hong He; Kathryn Ruisaard; Sijie Lu; James Wygant; Bradley W McIntyre; Qing Ma; Dan Li; Lisa St John; Karen Clise-Dwyer; Jeffrey J Molldrem
Journal:  Blood       Date:  2011-02-04       Impact factor: 22.113

Review 6.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

7.  Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Authors:  Tao Dao; Su Yan; Nicholas Veomett; Dmitry Pankov; Liang Zhou; Tatyana Korontsvit; Andrew Scott; Joseph Whitten; Peter Maslak; Emily Casey; Taochao Tan; Hong Liu; Victoria Zakhaleva; Michael Curcio; Ekaterina Doubrovina; Richard J O'Reilly; Cheng Liu; David A Scheinberg
Journal:  Sci Transl Med       Date:  2013-03-13       Impact factor: 17.956

8.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Authors:  Martin A Pule; Barbara Savoldo; G Doug Myers; Claudia Rossig; Heidi V Russell; Gianpietro Dotti; M Helen Huls; Enli Liu; Adrian P Gee; Zhuyong Mei; Eric Yvon; Heidi L Weiss; Hao Liu; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Nat Med       Date:  2008-11-02       Impact factor: 53.440

9.  CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors:  Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

10.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245
View more
  5 in total

1.  Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.

Authors:  Laura F Hutchins; Issam Makhoul; Peter D Emanuel; Angela Pennisi; Eric R Siegel; Fariba Jousheghany; Xueyan Guo; Anastas D Pashov; Behjatolah Monzavi-Karbassi; Thomas Kieber-Emmons
Journal:  Oncotarget       Date:  2017-10-23

Review 2.  Current Immunotherapies for Sarcoma: Clinical Trials and Rationale.

Authors:  Demytra Mitsis; Valerie Francescutti; Joseph Skitzki
Journal:  Sarcoma       Date:  2016-09-14

3.  Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?

Authors:  Katherine D Cummins; Saar Gill
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

Review 4.  CAR T-cell immunotherapy: The path from the by-road to the freeway?

Authors:  Lynsey M Whilding; John Maher
Journal:  Mol Oncol       Date:  2015-10-23       Impact factor: 6.603

Review 5.  Current status of cancer immunotherapy.

Authors:  K Kono
Journal:  J Stem Cells Regen Med       Date:  2014-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.